Cytomegalovirus (CMV): A Complete Deep Dive

Cytomegalovirus is one of the most consequential viruses you have almost certainly never heard of. It silently infects the majority of the global population, hides in the body for life, causes no symptoms in most healthy people — and yet it is the leading infectious cause of birth defects in the developed world, a major killer of transplant recipients, and a virus so immunologically sophisticated that it dedicates more of its genome to evading host defenses than any other known human pathogen.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.

This article is a detailed companion to our herpesvirus overview, which covers CMV briefly alongside the eight human herpesviruses. Here we go deep.

---

What Is CMV? Taxonomy and Genome

Cytomegalovirus — formally Human Herpesvirus 5 (HHV-5) — belongs to the Betaherpesvirinae subfamily. Along with HHV-6 and HHV-7, it forms the betaherpesvirus lineage, characterized by a narrow host range, slow replication cycle, and a particular tropism for secretory glands and myeloid cells.

CMV carries the largest genome of any human herpesvirus: approximately 236 kilobases of double-stranded DNA encoding an estimated 235 genes. For comparison, the Epstein-Barr virus (a gammaherpesvirus) encodes roughly 80 genes; herpes simplex type 1 encodes about 74. CMV's genomic excess is not redundancy — a remarkable fraction of those extra genes are dedicated to one purpose: immune evasion.

Structurally, CMV follows the herpesvirus blueprint:

• Core: linear dsDNA genome
• Capsid: icosahedral protein shell
• Tegument: a thick proteinaceous layer packed with viral effector proteins injected immediately upon cell entry
• Envelope: a lipid bilayer studded with glycoproteins (gB, gH/gL/gO, gM/gN) used for cell attachment and fusion

---

The Immune Evasion Masterclass

No human virus has invested more evolutionary resources in immune evasion than CMV. Estimates suggest that roughly a third of its genome — over 70 genes — serves immunomodulatory functions. This is not incidental; it reflects millions of years of co-evolution with primate immune systems.

Key evasion strategies include:

MHC class I downregulation. CMV encodes at least four proteins (US2, US3, US6, US11) that each independently interfere with MHC-I antigen presentation, ensuring infected cells are invisible to cytotoxic T lymphocytes. Four redundant mechanisms for one goal — a sign of how critical this is to viral survival.

NK cell evasion. Natural killer cells normally kill cells that lose MHC-I (the "missing self" signal). CMV counters this by encoding MHC-I decoys: UL18 mimics human MHC-I to engage inhibitory NK receptors, while other proteins modulate activating NK ligands.

Complement evasion. The glycoprotein gC1q-R binds complement component C1q to prevent the complement cascade from targeting infected cells.

Cytokine manipulation. CMV encodes a viral IL-10 homolog (cmvIL-10) that suppresses proinflammatory cytokine production, and encodes chemokine receptors (US27, US28) that act as chemokine "sinks," disrupting the immune-cell recruitment signals that would normally arrive at infection sites.

Inhibition of apoptosis and autophagy. Multiple CMV proteins block intrinsic and extrinsic apoptotic pathways, keeping infected cells alive long enough for viral replication to complete.

The result: a virus that can persist indefinitely in a host with a fully intact immune system — and explode into life-threatening disease the moment that immune system weakens.

---

Latency: Hiding in Myeloid Cells

Like all herpesviruses, CMV establishes lifelong latency after primary infection. Unlike HSV (which hides in neurons) or EBV (which hides in B cells), CMV establishes latency primarily in CD34+ hematopoietic progenitor cells and CD14+ monocytes — the myeloid lineage.

This location is strategically brilliant. Monocytes circulate through blood and tissues constantly. When a monocyte differentiates into a macrophage or dendritic cell, the change in cellular environment can reactivate latent CMV — disseminating it to new tissues. Immunosuppression, physical stress, or co-infection can trigger the same reactivation.

During latency, only a limited set of viral genes are expressed — enough to maintain the viral genome and modulate the cellular environment, but not enough to produce new virions. The full viral replication program (lytic replication) is suppressed.

This latency reservoir cannot currently be eliminated. Once infected, always infected.

---

Transmission Routes

CMV spreads through close contact with bodily fluids. Primary routes include:

Transmission Route	Key Context
Saliva	Most common; kissing, shared utensils, childcare
Urine	Young children shed high titers; risk for pregnant caregivers
Breast milk	Major route for postnatal infant acquisition
Sexual contact	Semen and cervicovaginal secretions contain high viral loads
Blood transfusion	Risk greatly reduced by leukoreduction and donor screening
Organ/stem cell transplant	Donor-derived virus in a seronegative recipient is highest risk
Transplacental (congenital)	Occurs during maternal primary infection or reactivation

Healthy adults acquiring CMV via saliva or sexual contact typically experience a mild mononucleosis-like illness (fever, fatigue, swollen lymph nodes) or no symptoms at all. The virus is then controlled by the immune system, which establishes a memory T-cell response of remarkable magnitude — CMV-specific T cells can constitute 10–20% of the entire memory CD8+ T-cell pool in older adults.

---

Congenital CMV: The Silent Epidemic

This is where CMV's public health significance becomes acute. To understand how viruses work generally, including replication mechanisms, see our dedicated explainer. Congenital CMV is a special case with devastating consequences.

Congenital CMV (cCMV) occurs when CMV crosses the placenta during pregnancy. It affects approximately 1 in 200 live births in the United States — making it more common than:

• Down syndrome (~1 in 700)
• Spina bifida (~1 in 2,700)
• Fetal alcohol syndrome (~1 in 1,000 by some estimates)

Despite this prevalence, awareness among pregnant women remains startlingly low. Surveys consistently find that fewer than 10% of pregnant women have heard of congenital CMV.

Who Is at Risk?

Primary maternal infection during pregnancy carries the highest transmission risk (~30–40%) and the worst fetal outcomes. However, non-primary infection (reactivation or reinfection with a new strain in a seropositive woman) also causes congenital CMV — accounting for the majority of cases in high-seroprevalence populations.

What Happens to the Baby?

Of every 200 babies born with cCMV:

• ~85% will be asymptomatic at birth — but are still at risk for late-onset sequelae
• ~15% will have symptomatic disease at birth — petechiae, jaundice, hepatosplenomegaly, microcephaly, brain calcifications, chorioretinitis

Of all babies born with cCMV (symptomatic and asymptomatic combined), approximately 20–25% will develop permanent disabilities, including:

• Sensorineural hearing loss — the most common sequela; CMV accounts for 10–20% of all childhood sensorineural hearing loss and is the leading non-genetic cause
• Cognitive impairment and intellectual disability
• Cerebral palsy
• Visual impairment
• Epilepsy

A key nuance: late-onset hearing loss can develop months to years after birth in babies who appeared normal as newborns. This is why universal CMV screening at birth — and follow-up audiology — is increasingly recommended but not yet standard practice in most countries.

Daycare and the Pregnant Parent Problem

Young children (ages 1–3) are prolific CMV shedders. They shed virus in urine and saliva at high titers, often for months after primary infection — and they give no visible indication of doing so. Parents and childcare workers in close contact with toddlers face significantly elevated CMV exposure.

Studies show that women who work in daycare or have young children at home have a 10–20% annual risk of primary CMV infection during seronegative pregnancy. Hygiene measures — handwashing after diaper changes, not sharing food or utensils with young children, avoiding contact with saliva — demonstrably reduce transmission risk, but public health messaging on this remains inadequate.

---

CMV in Immunocompromised Patients

Transplant Recipients

CMV is the most clinically significant viral pathogen in solid organ and hematopoietic stem cell transplantation. The highest-risk scenario is a CMV-seropositive donor paired with a CMV-seronegative recipient (D+/R-): the transplanted organ carries latent CMV, the recipient has no CMV-specific immunity, and immunosuppressive therapy prevents the recipient from building one.

Without prophylaxis, D+/R- solid organ transplant recipients face a >50% risk of CMV disease. Manifestations include CMV pneumonitis, hepatitis, colitis, retinitis, and encephalitis — any of which can be fatal.

Prevention strategies fall into two camps:

• Universal prophylaxis: antiviral drugs (valganciclovir, ganciclovir) given to all high-risk recipients for a defined period (typically 3–6 months post-transplant)
• Preemptive therapy: regular monitoring of CMV viral load by PCR; treatment initiated only if viral load exceeds a threshold before clinical disease appears

Both strategies have trade-offs. Universal prophylaxis can cause bone marrow suppression and is expensive; it also shifts CMV disease to a "late" (post-prophylaxis) window. Preemptive therapy requires infrastructure for frequent monitoring.

Drug-resistant CMV is an emerging crisis. Ganciclovir resistance (driven by mutations in UL97 kinase and UL54 polymerase genes) complicates management of refractory cases. Two newer agents address this:

• Letermovir (approved 2017): targets the CMV terminase complex — a viral enzyme with no human homolog, reducing off-target toxicity. Used for prophylaxis in CMV-seropositive hematopoietic stem cell transplant recipients.
• Maribavir (approved 2021): inhibits UL97, the viral kinase required for DNA encapsidation and nuclear egress. Approved specifically for refractory or resistant CMV infection in transplant patients — a population with previously very limited options.

CMV and HIV: Historical and Modern Context

Before the advent of antiretroviral therapy (ART), CMV retinitis was one of the most feared complications of AIDS. In patients with CD4+ T-cell counts below 50 cells/µL, CMV reactivation — particularly in the retina — caused progressive, painless vision loss and blindness in a substantial proportion of AIDS patients.

The introduction of ART in the mid-1990s transformed this picture. By restoring CD4 counts, ART allows the immune system to control CMV reactivation. CMV retinitis rates in the developed world have fallen by over 90% since the pre-ART era. It remains a significant problem in resource-limited settings where ART access is incomplete. For a broader look at HIV virology, see our HIV explainer.

---

The CMV Vaccine Race

There is no licensed CMV vaccine. This is widely considered one of the most significant unmet needs in vaccinology.

The Institute of Medicine ranked a CMV vaccine as the highest-priority vaccine development effort in the United States based on projected lives improved and economic cost of congenital CMV disability. That ranking was issued in 2000. A quarter-century later, we still have no vaccine.

Why Is It Hard?

CMV's immune evasion sophistication makes vaccine design non-trivial. The virus establishes latency in immunologically competent individuals despite robust natural immune responses — meaning natural infection is a poor model for "protective immunity." A vaccine must induce better-than-natural immunity, or at least sufficient immunity to reduce transplacental transmission.

Neutralizing antibody targets are complex: the pentameric complex (gH/gL/UL128/UL130/UL131A) mediates entry into epithelial and endothelial cells and is the dominant target of serum-neutralizing antibodies in naturally infected individuals. Vaccines that include the pentameric complex produce far stronger neutralizing antibody responses than gB-alone vaccines.

Moderna's mRNA-1647: The Frontrunner

Moderna's mRNA-1647 is currently the most advanced CMV vaccine candidate. It encodes:

• gB (glycoprotein B) — the major fusion protein, target of broadly neutralizing antibodies
• The pentameric complex (five subunits: gH, gL, UL128, UL130, UL131A)

Phase 2 data published in the New England Journal of Medicine showed approximately 50% efficacy in reducing CMV infection among seronegative women of childbearing age. While this may seem modest, a 50% reduction in primary CMV infection during pregnancy could prevent tens of thousands of congenital infections annually in the U.S. alone.

Phase 3 trials are ongoing. If efficacy and safety data hold, mRNA-1647 could become the first licensed CMV vaccine — representing a major public health milestone. The target population most likely to receive initial recommendations would be seronegative adolescent girls and women of childbearing age, where preventing primary infection during pregnancy has the greatest impact.

---

CMV Population Biology: Seroprevalence and Strain Diversity

CMV seroprevalence (the proportion of the population with antibodies indicating past infection) ranges from 40–60% in high-income countries to 80–100% in low- and middle-income countries. In the U.S., approximately 50–60% of adults are seropositive; in sub-Saharan Africa and parts of Asia, rates approach 100%.

CMV exhibits significant strain diversity. Unlike influenza (where antigenic drift drives epidemics), CMV strains differ substantially in genome sequence — recombination between strains is common and creates hyperdiverse field isolates. This complicates vaccine development: a vaccine designed around one strain's antigens must cross-protect against multiple genetically distinct circulating strains.

---

Comparison: CMV vs. Other Herpesviruses

Feature	CMV (HHV-5)	HSV-1 (HHV-1)	EBV (HHV-4)	VZV (HHV-3)
Subfamily	Beta	Alpha	Gamma	Alpha
Genome size	~236 kb / ~235 genes	~152 kb / ~74 genes	~172 kb / ~80 genes	~125 kb / ~70 genes
Latency site	Myeloid progenitors, monocytes	Sensory neurons	B lymphocytes	Sensory neurons
Immune evasion genes	~70+	~10–15	~20	~10
Main disease (healthy)	Mononucleosis (mild/none)	Oral herpes, genital herpes	Infectious mononucleosis	Chickenpox / shingles
Main disease (immunocomp.)	Pneumonitis, retinitis, colitis	Encephalitis	Lymphoma (EBV-associated)	Disseminated VZV
Congenital risk	High (leading infectious birth defect)	Low (neonatal HSV, rare)	Very low	Low
Licensed vaccine	No	No	No	Yes (Shingrix for VZV)

---

Frequently Asked Questions

Q: Can CMV be cured or eliminated from the body? A: No. Once CMV establishes latency in myeloid cells, it persists for life. Current antiviral drugs (ganciclovir, valganciclovir, letermovir, maribavir) suppress active viral replication but do not eliminate the latent reservoir. Research into latency-reversing agents and immune-based clearance strategies is ongoing but not yet clinically available.

Q: Should pregnant women be tested for CMV? A: Most national guidelines do not currently recommend universal CMV screening in pregnancy, partly because there are limited interventions available after maternal infection is detected. However, this is an active area of debate. Valacyclovir given to CMV-seropositive pregnant women has shown promise in reducing congenital transmission in some studies. Testing is recommended if a pregnant woman develops a mononucleosis-like illness.

Q: How common is congenital CMV compared to other birth defects? A: Congenital CMV affects approximately 1 in 200 births — making it more prevalent than Down syndrome (1 in 700), spina bifida (1 in 2,700), and several other conditions that receive far greater public awareness and research funding.

Q: Why do daycare workers and parents of toddlers face elevated CMV risk? A: Young children (aged 1–3) shed CMV in saliva and urine at very high titers, often for months, typically without any symptoms. Close contact — changing diapers, sharing food, being kissed — creates frequent exposure opportunities. Handwashing and avoiding contact with a child's saliva or urine significantly reduces, though doesn't eliminate, this risk.

Q: What is D+/R- CMV status in transplantation and why does it matter? A: D+/R- means the organ donor is CMV-seropositive (latent virus present in the donated organ) while the recipient is CMV-seronegative (no prior infection, no immunity). This is the highest-risk combination: latent donor virus can reactivate in the recipient, who has no pre-existing CMV-specific T cells to control it, and immunosuppressive drugs prevent an effective immune response from developing. Without antiviral prophylaxis, CMV disease rates in this group exceed 50%.

Q: What makes CMV's immune evasion unusually sophisticated? A: CMV dedicates an estimated 70+ genes to immune evasion — more than any other known human virus. It simultaneously blocks MHC class I antigen presentation (hiding from T cells), produces MHC decoys (hiding from NK cells), encodes a viral IL-10 homolog to suppress inflammation, acts as a chemokine "sink" to disrupt immune cell recruitment, and blocks apoptosis in infected cells. This redundant, multilayered strategy reflects deep co-evolutionary history with primate immune systems.

Q: What is the current status of CMV vaccines? A: No CMV vaccine is currently licensed. Moderna's mRNA-1647 (encoding gB and the pentameric complex) is the most advanced candidate, with Phase 2 data showing approximately 50% efficacy in seronegative women. Phase 3 trials are ongoing. If successful, it would represent the first licensed CMV vaccine — a major public health achievement given the burden of congenital CMV.

Q: Can breastfeeding transmit CMV to newborns? A: Yes. CMV is present in breast milk of seropositive women, particularly during viral reactivation in the postpartum period. For healthy term infants, postnatal CMV acquisition via breast milk is generally benign — the infant's maturing immune system, plus passive antibodies from breast milk itself, controls the infection. However, for very premature infants (born before 30–32 weeks), postnatal CMV acquired via breast milk can cause significant disease, and some neonatal units pasteurize or freeze breast milk for this population.

---

Conclusion

Cytomegalovirus is a paradox: nearly universal, usually harmless, yet responsible for more childhood disability than any other infectious agent and a persistent threat to the immunocompromised. Its genomic sophistication — the largest human herpesvirus genome, dedicated in significant part to defeating the very immune system it lives within — makes it a remarkable subject of study and a formidable clinical adversary.

The coming years may finally deliver the long-awaited CMV vaccine. If mRNA-1647 or a comparable candidate reaches licensure with even moderate efficacy, the downstream reduction in congenital CMV cases, hearing loss, and neurodevelopmental disability could make it among the most impactful vaccines introduced in a generation.

---

Sources

1. WHO — Cytomegalovirus (CMV) and Congenital CMV Infection. who.int
2. CDC — Cytomegalovirus (CMV) and Congenital CMV Infection. cdc.gov/cmv
3. Revello MG, Gerna G. Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. J Clin Virol. 2004;29(2):71–83.
4. Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol. 2006;35(2):226–231.
5. Pass RF et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360(12):1191–1199.
6. Kauvar LM et al. Importance of occupational CMV exposure for seronegative women. Infect Dis Obstet Gynecol. 2009.
7. Kotton CN et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931.
8. Maertens J et al. Maribavir for Refractory or Resistant Cytomegalovirus Infections. N Engl J Med. 2021;385:1522–1532.
9. Kuter BJ et al. Moderna mRNA-1647 CMV Vaccine Phase 2 Immunogenicity. N Engl J Med. 2023 (interim results).
10. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19:759–773.

---

Read next:

• Shingles & Varicella-Zoster Virus: Deep Dive
• Adenovirus Explained: The Hardy Virus Behind Many Diseases
• Epstein-Barr Virus (EBV): The Virus Inside Us All